Stockreport

Wayfinder Biosciences Advances Collaboration with Daiichi Sankyo on Key Neurodegeneration Target to Second Phase [Yahoo! Finance]

DAIICHI SANKYO S/ADR  (DSNKY) 
PDF RNA level, today announced the advancement to the second phase of its research collaboration with Daiichi Sankyo (TSE: 4568) through its Daiichi Sankyo Research Institut [Read more]